Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Lascoux

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Plos One|August 10, 2016
Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 ParticlesChiraz Hamimi, Annie David, Pierre Versmisse, et al.
The Journal of Antimicrobial Chemotherapy|December 18, 2015
Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppressionPierre Gantner, Laurence Morand-Joubert, Charlotte Sueur, et al.
The Journal of Antimicrobial Chemotherapy|April 23, 2015
Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remissionAntoine Chéret, Charline Bacchus-Souffan, Veronique Avettand-Fenoël, et al.
AIDS (London, England)|May 30, 2024
Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirineEmma Rubenstein, Myriam Diemer, Lauriane Goldwirt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2014
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trialLaurent Cotte, Joséphine Braun, Caroline Lascoux-Combe, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 15, 2024
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022Romain Palich, Andrés Arias-Rodríguez, Martin Duracinsky, et al.
Plos One|May 22, 2013
A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infectionCharline Bacchus, Antoine Cheret, Véronique Avettand-Fenoël, et al.
European Journal of Gastroenterology & Hepatology|April 30, 2019
Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohortMathieu Chalouni, Philippe Sogni, Patrick Miailhes, et al.
The Lancet. Infectious Diseases|February 22, 2015
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trialAntoine Chéret, Georges Nembot, Adeline Mélard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2016
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH CohortPhilippe Sogni, Camille Gilbert, Karine Lacombe, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Plos One|August 10, 2016
Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 ParticlesChiraz Hamimi, Annie David, Pierre Versmisse, et al.
The Journal of Antimicrobial Chemotherapy|December 18, 2015
Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppressionPierre Gantner, Laurence Morand-Joubert, Charlotte Sueur, et al.
The Journal of Antimicrobial Chemotherapy|April 23, 2015
Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remissionAntoine Chéret, Charline Bacchus-Souffan, Veronique Avettand-Fenoël, et al.
AIDS (London, England)|May 30, 2024
Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirineEmma Rubenstein, Myriam Diemer, Lauriane Goldwirt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2014
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trialLaurent Cotte, Joséphine Braun, Caroline Lascoux-Combe, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 15, 2024
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022Romain Palich, Andrés Arias-Rodríguez, Martin Duracinsky, et al.
Plos One|May 22, 2013
A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infectionCharline Bacchus, Antoine Cheret, Véronique Avettand-Fenoël, et al.
European Journal of Gastroenterology & Hepatology|April 30, 2019
Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohortMathieu Chalouni, Philippe Sogni, Patrick Miailhes, et al.
The Lancet. Infectious Diseases|February 22, 2015
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trialAntoine Chéret, Georges Nembot, Adeline Mélard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2016
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH CohortPhilippe Sogni, Camille Gilbert, Karine Lacombe, et al.
Pageof 8